Dianabol vs Kisspeptin
Well Studied vs Emerging
synergistic Mechanism-based · 49% Kisspeptin helps manage estrogen conversion from Dianabol. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Dianabol Kisspeptin
Weight 300.44 Da 1,213.42 Da (KP-10) / 6,087 Da (KP-54)
Half-life ~4-6 hours ~4 minutes (KP-10), ~28-32 minutes (KP-54)
Chain — 10-54 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Neuropeptide family (RFamide)
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Kisspeptin
01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
Kisspeptin
100-200 mcg per injection / Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly
Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician
Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Kisspeptin
Minimal acute side effects reported
Potential mild cardiovascular effects
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Not recommended during pregnancy or breastfeeding
Caution with cardiovascular disease history
Daily dosing causes receptor desensitization
Research Evidence
Dianabol Kisspeptin
Status Well Studied Emerging
References 5 studies 4 studies
Latest 2017 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.